Abstract: Provided are an apparatus for producing inorganic powder, and a method of producing inorganic powder by using such. The apparatus includes a vaporization part where a condensed-phase precursor is vaporized to obtain a gas-phase precursor, a partial precipitation part where the gas-phase precursor obtained in the vaporization part is partially precipitated to a condensed phase, and a reaction part where the gas-phase precursor remaining after being partially precipitated to a condensed phase in the partial precipitation part reacts with a reaction gas to obtain inorganic powder. An equilibrium vapor pressure of the gas-phase precursor in the partial precipitation part is lower than a vapor pressure of the gas-phase precursor obtained in the vaporization part, and an equilibrium vapor pressure of the precursor in the reaction part is equal to or higher than a vapor pressure of the gas-phase precursor partially precipitated to a condensed phase in the partial precipitation part.

Abstract: The present invention relates to a novel quinoline compound and a use thereof and to a novel quinoline compound exhibiting CYP4A inhibition activity and a use thereof for preventing, alleviating, treating a metabolic disease. The compound disclosed in the present invention has a remarkable effect of inhibiting CYP4A and exhibits the activities of promoting the absorption of glucose into hepatocytes, inhibiting fat accumulation in hepatocytes, suppressing endoplasmic reticulum-induced reactive oxygen species, and treating steatohepatitis, and thus can be very advantageously used for developing therapeutics for metabolic diseases such as diabetes mellitus and fatty liver.

Abstract: The present invention relates to a composition comprising a CYP4A-inhibiting compound as an active ingredient for preventing or treating metabolic diseases, more specifically to a composition comprising the compound expressed by chemical formula 1 of the present invention or pharmaceutically acceptable salt thereof as an active ingredient for preventing, ameliorating or treating metabolic diseases.

Abstract: The present invention relates to a recurring glioblastoma multiforme marker miRNA for diagnosing recurring glioblastoma multiforme, and more specifically, to a composition for screening the miRNA marker, which is specific to the recurring glioblastoma multiforme and comprises an agent for detecting the presence of the marker, a kit, and to a method for diagnosing the recurring glioblastoma multiforme using same. The method for diagnosing the recurring glioblastoma multiforme by using the recurring glioblastoma multiforme marker miRNA, according to the present invention, provides glioblastoma markers, which can diagnose the occurrence of the recurring glioblastoma multiforme, thereby providing useful material for managing treatment and prognosis of the recurring glioblastoma multiforme. In addition, the diagnosis markers for the recurring glioblastoma multiforme can be used for development and research of an anticancer agent specific to the recurring glioblastoma multiforme.

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetes or fatty liver comprising a CYP4A (cytochrome P450A) inhibitor as an active ingredient. The compound of the present invention has activities of promoting glucose uptake into hepatocytes, inhibiting fat accumulation in liver cells, and inhibiting reactive oxygen production in mitochondria, and thus can be very usefully used for the development of a therapeutic agent for diabetes or fatty liver.

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetes or fatty liver comprising a CYP4A (cytochrome P450A) inhibitor as an active ingredient. The compound of the present invention has activities of promoting glucose uptake into hepatocytes, inhibiting fat accumulation in liver cells, and inhibiting reactive oxygen production in mitochondria, and thus can be very usefully used for the development of a therapeutic agent for diabetes or fatty liver.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes or fatty liver, and more specifically relates to a pharmaceutical composition for preventing or treating diabetes or fatty liver containing a CYP4A (cytochrome P450A) inhibitor as an active ingredient. According to the present invention, the CYP4A inhibitor suppresses endoplasmic reticulum stress, reduces the blood insulin concentration and suppresses apoptosis of liver cells, and hence exhibits effects in preventing or treating diabetes or fatty liver.

Abstract: The present invention relates to a recurring glioblastoma multiforme marker miRNA for diagnosing recurring glioblastoma multiforme, and more specifically, to a composition for screening the miRNA marker, which is specific to the recurring glioblastoma multiforme and comprises an agent for detecting the presence of the marker, a kit, and to a method for diagnosing the recurring glioblastoma multiforme using same. The method for diagnosing the recurring glioblastoma multiforme by using the recurring glioblastoma multiforme marker miRNA, according to the present invention, provides glioblastoma markers, which can diagnose the occurrence of the recurring glioblastoma multiforme, thereby providing useful material for managing treatment and prognosis of the recurring glioblastoma multiforme. In addition, the diagnosis markers for the recurring glioblastoma multiforme can be used for development and research of an anticancer agent specific to the recurring glioblastoma multiforme.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes or fatty liver, and more specifically relates to a pharmaceutical composition for preventing or treating diabetes or fatty liver containing a CYP4A (cytochrome P450A) inhibitor as an active ingredient. According to the present invention, the CYP4A inhibitor suppresses endoplasmic reticulum stress, reduces the blood insulin concentration and suppresses apoptosis of liver cells, and hence exhibits effects in preventing or treating diabetes or fatty liver.